Pharming Group Full Year 2023 Earnings: US$0.015 loss per share (vs US$0.021 profit in FY 2022)
Pharming Group (AMS:PHARM) Full Year 2023 Results
Key Financial Results
Revenue: US$245.3m (up 19% from FY 2022).
Net loss: US$10.1m (down by 174% from US$13.7m profit in FY 2022).
US$0.015 loss per share (down from US$0.021 profit in FY 2022).
PHARM Post-Clinical Trial Products
Approved (during full year): 1.
Launched (during full year): 1.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Pharming Group Earnings Insights
Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Europe.
Performance of the market in the Netherlands.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Before we wrap up, we've discovered 1 warning sign for Pharming Group that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
